 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...89101112131415161718...1920» |
- glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Human Herpesvirus 8-Associated Kaposi Sarcoma Developing in a Kidney Allograft from a Hepatitis C-Positive Donor (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3204;
He tested positive for HCV on post-transplant day 2 and was treated with sofosbuvir/velpatasvir for 12 weeks...He was treated pre-emptively for HCV with glecaprevir/pibrentsvir...Initial allograft biopsy was of poor quality but was suggestive of Banff IIA rejection; IV methylprednisone and anti-thymocyte globulin were administered...Public Health Service (PHS) increased risk donors may represent a subset of donors at especially high risk for HHV-8 transmission. Future investigation is needed into this population to determine if post-transplant HHV-8 PCR monitoring or adjustments in immunosuppression are needed for kidney transplant recipients of PHS increased risk organs.
- ezetimibe / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Direct Acting Antiviral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C-Negative Kidney Transplant Recipients (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3196;
A 7-day DAA prophylaxis is effective in preventing donor-derived HCV transmission, can result in significant cost-savings and increase access to transplants. Adding ezetimibe to SOF/VEL did not provide an additional benefit in preventing viral transmission.
- pibrentasvir (ABT-530) / AbbVie, Vistide (cidofovir) / Gilead, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] BK Polyomavirus Nephropathy After Kidney Transplantation from HCV-Infected Donor to HCV-Uninfected Recipient (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3192;
He received glecaprevir and pibrentasvir (March 2019) for a total of 12 wk...He was started on cidofovir, levofloxacin and intravenous immunoglobulin, followed by a course of sofosbuvir/velpatasvir/voxilaprevir and ribavirin for a total of 12 wk, achieving SVR at 12 wk...His immunosuppressive regimen was intensified and graft function has remained stable. Discussion Our case report with close proximity of HCV treatment failure and severe BKPyV DNAemia/nephropathy supports the previous finding that transplantation from HCV infected donor kidneys to uninfected recipients may be a risk factor of BKPyV DNAemia/nephropathy.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] EFFICACY AND SAFETY OF HCV SEROPOSITIVE DONORS TO HCV SERONEGATIVE RECIPIENTS: A LARGE SINGLE CENTER ANALYSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1337;
HCV seropositive donor organs can be safely transplanted into seronegative patients with minimal complications up to 1 year post-transplant. This data supports the continued use of HCV‐seropositive grafts.
- lactulose / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] POLYMICROBIAL BACTEREMIA DUE TO ATYPICAL OPPORTUNISTIC ORGANISMS IN A PATIENT WITH CHRONIC HEPATITIS C AND END STAGE LIVER DISEASE. () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1026;
Gram stain results in diplococci, cocci, or coccobacilli that is usually O shaped due to peripheral staining. P.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] TIME FROM DIAGNOSIS TO TREATMENT IN VULNERABLE POPULATIONS VERSUS GENERAL POPULATION: DO WE TEST-AND-TREAT OUR HCV PATIENTS IN THE SAME WAY? () - Oct 11, 2020 - Abstract #AASLD2020AASLD_994;
This analysis shows that a quick treatment start is possible, both in general population and in vulnerable populations, supporting the feasibility of a TnT approach in all populations. New strategies should be considered to engage patients with mental disorders in this model of care more effectively.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] METABOLIC COMORBIDITIES AND OVERWEIGHT INFLUENCE STEATOSIS AFTER VIRAL ERADICATION BY DIRECT-ACTING ANTIVIRAL THERAPY (DAAS) IN PATIENTS WITH CHRONIC HEPATITIS C: EVALUATION BY CONTROLLED ATTENUATION PARAMETER (CAP) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_975;
after SVR the new onset or and the resolution of steatosis are closely related to the presence or absence of overweight and metabolic comorbidities. Patients who eradicate HCV by DAA need to be carefully followed up for the high risk of developing metabolic liver disease in a short time.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] VARIABLE ADHERENCE TO HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS TREATED WITH 8 VERSUS 12 WEEKS OF ANTIVIRAL THERAPY RESULTED IN HIGH RATES OF SVR () - Oct 11, 2020 - Abstract #AASLD2020AASLD_945;
PWID have high rates of SVR and adherence to HCV treatment. Adherence rates were similar for whether they are prescribed an 8- or 12-week course of therapy.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] VALUE OF SOF/VEL AS PANGENOTYPIC PANFIBROTIC HCV TREATMENT IN IMPLEMENTING A TEST AND TREAT STRATEGY IN PRISONS: REAL-WORLD CARE MANAGEMENT FROM 6 COUNTRIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_944;
SOF/VEL is a simple HCV treatment regimen resulting in high cure rates in the prison setting, harboring challenging to treat patients. The simplicity of this regimen creates an opportunity to further shorten the care cascade, treat inmates quicker after diagnosis, and potentially reduce the LTFU rate.
- Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
[VIRTUAL] SIGNIFICANCE OF IP-10 MEASUREMENT IN PREDICTING POST-DAA TREATMENT LIVER FUNCTION IN PATIENTS WITH HCV-DECOMPENSATED LIVER CIRRHOSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_937;
Serum IP-10 levels were decreased in CH/cLC cases upon DAA therapy while such a clear relationship was not observed in dLC cases. Importantly, it was demonstrated that Child-Pugh score was not improved in the dLC cases without IP-10 decrease, indicating that IP-10 dynamics may be useful in predicting liver function after DAA therapy in dLC cases.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
[VIRTUAL] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION () - Oct 11, 2020 - Abstract #AASLD2020AASLD_932;
P2
Treatment with SOF/VEL/VOX for 8 weeks in DAA-naïve patients aged 12 to 17 years without cirrhosis resulted in 100% SVR and was well tolerated overall. Although no DAA-experienced patients were studied, SOF/VEL/VOX may provide a treatment option for adolescents with chronic HCV infection regardless of prior treatment experience with a DAA.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTION IN ADOLESCENTS AND CHILDREN AGED 3 TO 17 YEARS OLD THROUGH 24 WEEKS POST-TREATMENT () - Oct 11, 2020 - Abstract #AASLD2020AASLD_931;
P2
A smaller, low-dose tablet and oral granule formulations have been developed to facilitate dosing in younger children. SOF/VEL is a simple, pangenotypic, fixed dose combination regimen that promises to be a beneficial treatment option for children as young as 3 years of age.
- Copegus (ribavirin) / Bausch Health, Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
[VIRTUAL] RETREATMENT FOR HCV: PRELIMINARY RESULTS FROM A RETROSPECTIVE ANALYSIS OF POOLED NATIONAL PROGRAM DATA ACROSS LOW- AND MIDDLE-INCOME COUNTRIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_930;
Additional retrospective data may be collected to study strengths and limitations of these SLT options. These preliminary data can reassure the public, clinicians, and policymakers that effective and affordable SLT options are feasible for national programs in diverse LMICs settings.
- paritaprevir/ritonavir (ABT-450/r) / AbbVie
[VIRTUAL] OUTCOMES OF HEPATITIS C TREATMENT ARE SIMILAR IN CANADIAN INDIGENOUS PEOPLE COMPARED TO NON-INDIGENOUS PATIENTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_926;
Importantly, DAA SVR rates were comparable to the non-indigenous control group. These real-world effectiveness data add to the limited global data on DAA effectiveness in Indigenous people, and suggests DAA-based HCV microelimination in Indigenous people is possible.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] LONG TERM FOLLOW-UP OF SAFETY AND EFFICACY OF SOFOSBUVIR-BASED HCV DAAS IN PEDIATRIC PATIENTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_924;
P=N/A
Interim data are reported from a 5-year registry study (NCT02510300) in pediatric patients who received treatment for chronic hepatitis C virus (HCV) infection with sofosbuvir (SOF) +ribavirin (RBV), ledipasvir/sofosbuvir (LDV/SOF) ±RBV, or sofosbuvir/velpatasvir (SOF/VEL) in a prior clinical trial. HCV treatment with the DAAs SOF, LDV/SOF and SOF/VEL resulted in durable SVR in pediatric patients aged 3 to 17 years and did not impact growth or development through a median of 3 years and up to 5 years post-treatment.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] HCV ELIMINATION IN HOMELESS PATIENTS IS POSSIBLE: A POOLED REAL-WORLD ANALYSIS OF HOMELESS PATIENTS WITH HCV TREATED WITH 12 WEEKS SOFOSBUVIR/VELPATASVIR (SOF/VEL) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_916;
High SVR rates with SOF/VEL as a simple, potent HCV treatment option were observed in a homeless population considered difficult to engage in care and therapy. A test-and-treat strategy, easily implemented with SOF/VEL, could further enhance the population-level efficacy of HCV therapy by reducing the rate of non-virologic failure due to LTFU and related factors.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] HCV ELIMINATION IN ACTIVE PWID: SOF/VEL AS A SIMPLE TOOL TO IMPLEMENT A TEST AND TREAT APPROACH IN THIS VULNERABLE POPULATION () - Oct 11, 2020 - Abstract #AASLD2020AASLD_915;
LTFU remains a challenge in this population. The simplicity of the SOF/VEL approach allowing for shortening of the patient care cascade and rapid treatment starts with high cure rates may help address this important issue.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] EVALUATION OF HOST AND VIRAL FACTORS IN ACHIEVING SUSTAINED VIROLOGIC RESPONSE (SVR) WITH DIRECT-ACTING ANTIVIRALS (DAAS) IN HEPATITIS C VIRUS (HCV) PATIENTS IN THE ILLINOIS DEPARTMENT OF CORRECTIONS (IDOC) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_913;
Despite the presence of factors previously associated with inferior response, study data for this population show no significant difference in the achievement of SVR for incarcerated HCV patients regardless of baseline characteristics. Due to the high achievement of SVR, DAAs should continue to be the standard of care for HCV infections in the correctional population.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] ESTABLISHMENT OF AN OUTREACH, GROUPING HEALTH CARE SYSTEM WITH SOFOSBUVIR/VELPATASVIR TO ACHIEVE MICRO-ELIMINATION OF HCV IN HEMODIALYSIS CENTERS (ERASE-C) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_911;
P, P3
Sofosbuvir/velpatasvir was highly effective and safe for uremic HCV patients. (ClinicalTrials.gov Identifier: NCT03803410 and NCT03891550)
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH PSYCHIATRIC DISORDERS: INTEGRATED ANALYSIS -FROM PHASE 2 AND 3 CLINICAL TRIALS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_907;
Patients with HCV and psychiatric disorders were included from 15 phase 2 and 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-5, POLARIS-2, POLARIS-3, POLARIS-4, GS-US-342-0102, GS-US-342-0109, GS-US-342-1446, GS-US-342-1518, GS-US-342-1521, GS-US-342-1522, GS-US-342-2097, GS-US-342-4062), treated with SOF/VEL for 12 weeks without ribavirin...Approximately 78% of patients were being treated for the psychiatric condition, and 12.5% of patients (n=73) on antipsychotics, with quetiapine the most commonly prescribed (n=30)... In this historically harder to treat population with psychiatric disorders, SOF/VEL for 12 weeks is a simple, highly effective and well-tolerated HCV treatment providing high cure rates similar to general population thus enabling HCV elimination.
- sofosbuvir/velpatasvir / Generic mfg., clozapine / Generic mfg.
[VIRTUAL] EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR (SOF/VEL) IN PATIENTS WITH CHRONIC HCV INFECTION AND PSYCHIATRIC DISORDERS: REAL-WORLD CARE MANAGEMENT FROM 6 COUNTRIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_905;
Adult patients suffering ≥1 MD from 29 cohorts in 6 countries without history of decompensation or prior NS5A-inhibitor exposure who were treated for HCV with 12 weeks SOF/VEL without ribavirin before 02/2020 were included in this analysis...32% of patients used antipsychotics: quetiapine (43%), aripiprazole (11%), paliperidone (9%), clozapine (7%), unknown (30%).History of IV drug use was documented in 50% of patients, active use in 18%... SOF/VEL is a simple HCV treatment curing the majority of HCV patients with mental disorders and associated complicating factors, enabling HCV elimination in this high priority population.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] DRUG-DRUG INTERACTIONS (DDIS) UNDER HCV THERAPY: ANTIPSYCHOTIC DRUGS IN ADDICTED PATIENTS AND PATIENTS ON OPIOID SUBSTITUTION THERAPY (OST) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_903;
In particular for the neuroleptic quetiapine, which has an interaction potential with some HCV drugs, the number of prescriptions under HCV therapy decreases - and here especially under GLE/PIB and ELB/GZP therapy, indicating that potential interactions are taken into account in the clinical routine of HCV therapy. In mentally ill addicted patients, it is important to pay particular attention to DDIs in the context of their comedications when starting HCV therapy.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] DIRECTLY OBSERVED THERAPY FOR HEPATITIS C ALONGSIDE OPIOID AGONIST THERAPY AS AN EFFECTIVE MICRO-ELIMINATION STRATEGY IN VIENNA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_902;
Most common DAA combinations were sofosbuvir/velpatasvir (178, 38%), glecaprevir/pibrentasvir (165, 35.3%) and sofosbuvir/ledipasvir (63, 13.5%). HCV therapy according to the concept of DOT showed excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] CRUSHING AND SPLITTING DAAS FOR HCV TREATMENT: A CASE SERIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_900;
This case series provides evidence for safety and effectiveness with HCV DAA tablet manipulation. More data is needed to further inform practice and treatment decisions.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] COMEDICATIONS AND THEIR POTENTIAL DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL AGENTS IN HEPATITIS C PATIENTS ON HEMODIALYSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_899;
HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. EBR/GZR had the fewest and SOF/VEL/VOX had the most potential DDIs.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] ACTIVE DRUG USE IS NOT ASSOCIATED WITH TREATMENT FAILURE AMONG PWID PATIENTS WITH VARIABLE ADHERENCE TO HCV TREATMENT () - Oct 11, 2020 - Abstract #AASLD2020AASLD_895;
Information collected included HCV genotype, treatment regimen, use of opiate substitution therapy (OST; i.e. buprenorphine/naltrexone, methadone), active drug use (patient-reported or positive urine toxicology), adherence and SVR...The most commonly prescribed DAA regimens were: sofosbuvir-velpatasvir (N=11), sofosbuvir-ledipasvir (11 patients; 8 for 12 weeks and 3 for 8 weeks), glecaprevir-pibrentasvir for 8 weeks (N=21), elbasvir-grazoprevir (N=7) and other (N=12)... Among PWID patients who have variable adherence to HCV therapy, active drug use and maintenance on OST during treatment were not associated with treatment failure.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] 8 WEEKS VERSUS 12 WEEKS OF DIRECT-ACTING ANTIVIRAL THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C INFECTION () - Oct 11, 2020 - Abstract #AASLD2020AASLD_893;
Treatment with 8 weeks of GLE/PIB or LDV/SOF has excellent efficacy in noncirrhotic DDKT patients with HCV. These findings add to the growing evidence of equal efficacy with shorter treatment courses in most HCV patients.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] IMPROVEMENT IN SERUM ALBUMIN LEVELS AFTER DIRECT-ACTING ANTIVIRALS TREATMENT FOR PATIENTS WITH HEPATITIS C VIRUS-RELATED CIRRHOSIS DEPENDS ON THE BASELINE SERUM ALBUMIN LEVELS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_877;
The efficacy and safety of DAA treatment for patients with decompensated cirrhosis were comparable with those for patients with compensated cirrhosis. Improvement in serum albumin levels among patients with cirrhosis who achieved SVR might differ by the baseline serum albumin levels.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] DRUG-DRUG INTERACTIONS (DDIS) IN ITALIAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH PANGENOTYPIC DIRECT ACTING AGENTS (PDAAS): FOCUS ON CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM COMEDICATIONS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_869;
In real world practice, SOF/VEL is used preferably in older patients, with higher rates of comorbidities and comedications, mainly related to CV and CNS co-morbidities. Despite this, a proportion of contraindicated drugs lower than that of GLE/PIB was registered.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] DIRECT-ACTING ANTIVIRALS (DAAS) RESULTS IN ADVERSE LIPID PROFILE CHANGES IN CHRONIC HEPATITIS C PATIENTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_867;
Our study demonstrated significant increase in all components of lipid profile in both sofosbuvir + velpatasvir and sofosbuvir + daclatasvir group . This is the first study which has assessed the effect of velpatasvir on lipid profile in chronic hepatitis C patients.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] PILOT PROJECT TO ELIMINATE OF HEPATITIS B & C IN UZBEKISTAN – INTERIM RESULTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_664;
The simplified testing and treatment have allowed us to test thousands of patients in less than three months. The learnings from this program can be used to also shape other national hepatitis programs in low- & middle-income settings.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] COVID-19 IN PATIENTS WITH CHRONIC HEPATITIS C RECEIVING DAA THERAPY: INITIAL EXPERIENCE FROM A LONGITUDINAL SURVEY () - Oct 11, 2020 - Abstract #AASLD2020AASLD_427;
A preventive or curative role of DAA as postulated needs to be ascertained. Further, longitudinal randomized control trials are required to establish the role of anti-HCV DAAs in the management of COVID-19.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] ARE HCV ANTIBODIES POSITIVE CIRRHOTIC PATIENTS AT LOWER RISK OF DEATH AS COMPARED TO CIRRHOTIC OF DIFFERENT ETIOLOGIES WHEN INFECTED BY COVID-19? () - Oct 11, 2020 - Abstract #AASLD2020AASLD_411;
Pre-existing cirrhosis is associated with high mortality. Whether patients recently cured for HCV infection had a smaller exposure or were less vulnerable to COVID-19 as compared to patients with cirrhosis of metabolic origin deserves further investigation.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] HEPATITIS C VIREMIC ORGANS TRANSPLANTED INTO NON-VIREMIC RECIPIENTS; A REAL WORLD NURSE PRACTITIONER LED CLINIC () - Oct 11, 2020 - Abstract #AASLD2020AASLD_332;
Our review demonstrates that treatment managed by an APRN is successful and medications are well tolerated in this population. DAAs can be obtained in the real-world while adjusting for DDIs.
- | Daklinza (daclatasvir) / BMS
Journal, HEOR: Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. (Pubmed Central) - Oct 10, 2020
Allocating resources for DAA treatment for HCV genotype 1 and 6 is surely a rewarding public health investment in Vietnam. It is recommended that the government rapidly scale up treatment and enable financial accessibility for HCV patients.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
[VIRTUAL] Sofosbuvir/velpatasvir/voxilaprevir use for hepatitis C virus treatment at an urban academic medical center () - Oct 8, 2020 - Abstract #ASHP2020ASHP_386;
The cohort contained a high percent of difficult-to-cure cirrhotic and treatment-experienced patients with baseline resistance. The SVR rate did not differ by baseline patient characteristics or adherence, yet conclusions across groups are limited due to the small numbers in this patient population.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-World Evidence: Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. (Pubmed Central) - Oct 8, 2020
An SVR provided an improvement of the liver function in the majority of patients. However, large portosystemic shunt and hyperbilirubinemia were independent factors that interfered with the improvement in the CP score.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] LONG-TERM Cost-Effectiveness of the Sofosbuvir-Based Directing-Acting Antivirals in Treating Patients with Chronic Hepatitis C (CHC) in China- From a Healthcare Payer’S Perspective () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1910;
SOF-based regimens offer better economic benefits vs PR in China, and provide simpler treatment and broader eligibility vs other DAAs due to being protease inhibitor-free. From a payer’s perspective, SOF-based regimens are more suitable option for CHC treatment in China, with high potential to reduce disease burden and achieve HCV elimination.
- || Daklinza (daclatasvir) / BMS, sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. (Pubmed Central) - Sep 30, 2020
Old age and cirrhosis were significant predictors of reduced odds of SVR regardless of the regimen. Furthermore, the regimens were well tolerated in chronic HCV patients.
- || sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). (Pubmed Central) - Sep 26, 2020
In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, voxilaprevir (GS-9857) / Gilead
Journal: Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi. (Pubmed Central) - Sep 24, 2020
Furthermore, hepatotoxicity was not observed in Phase 3 clinical trials with voxilaprevir, consistent with our design strategy. Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, voxilaprevir (GS-9857) / Gilead, sofosbuvir/velpatasvir / Generic mfg.
Journal: Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi and Epclusa. (Pubmed Central) - Sep 24, 2020
VEL combined with sofosbuvir (SOF) is Epclusa, an STR with 98% cure-rates for genotype 1-6 HCV infected patients. Addition of the pan-genotypic HCV NS3/4A protease inhibitor voxilaprevir to SOF/VEL is the STR Vosevi, which affords 97% cure-rates for genotype 1-6 HCV patients who have previously failed another treatment regimen.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] An Unfortunate Association: Diffuse Large B-Cell Lymphoma With Chronic Hepatitis C () - Sep 15, 2020 - Abstract #ACG2020ACG_2967;
He was discharged with plans to start DAA therapy with Epclusa and close follow-up with GI to monitor for sustained virological response...Finally, initiating DAAs after chemotherapy in these cases helps to prevent recurrence of DLBCL once SVR is achieved. CT Scan of R-posterior Rib Mass 60mm x 64mm Rib Mass Biopsy DLBCL 100X H&E Rib Mass Biopsy DLBCL 200X Ki-67 IHC
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Diffuse Alveolar Hemorrhage in Hepatitis C-Related Mixed Cryoglobulinemic Vasculitis () - Sep 15, 2020 - Abstract #ACG2020ACG_2935;
Eventually, renal function improved, and she was discharged with sofosbuvir/velpatasvir for treatment of HCV...Diffuse alveolar hemorrhage is rapidly progressive and requires a high index of suspicion. Early bronchoscopy with bronchoalveolar lavage is critical for diagnosis and timely initiation of therapy.
- Sovaldi (sofosbuvir) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Successful Treatment of Fibrosing Cholestatic Hepatitis With Sofosbuvir and Velpatasvir in an Immunocompromised Patient After Chemotherapy for Diffuse Large B-Cell Lymphoma With Concurrent HIV and Hepatitis C () - Sep 15, 2020 - Abstract #ACG2020ACG_2919;
With DAA he was able to avoid progression to liver failure and has normalization of his liver function tests. Previous successfully treated cases have been described in post-transplant patients, and this case suggests that there is likely a role for DAA in the treatment of FCH in non-transplant patients.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] A Devastating Case of Hepatitis C-Induced Mixed Cryoglobulinemia () - Sep 15, 2020 - Abstract #ACG2020ACG_2832;
Sofosbuvir/velpatasvir was started for treatment of chronic Hepatitis C. HCV viral load was undetectable (< 15 IU/mL) after one week and there was no further spread of gangrene...These cases require early recognition and aggressive treatment to prevent progression to the extent of limb amputation and even death. This highlights the necessity of universal screening for Hepatitis C and portrays the devastating effects that delayed screening and therefore delayed treatment may have.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Factors Predicting Failure of Hepatitis C Therapy in a Diverse Urban Population () - Sep 15, 2020 - Abstract #ACG2020ACG_2576;
The antiviral treatments groups studied were ledipasvir/sofosbuvir (79%), sofosbuvir/velpatasvir (8.3%), elbasvir/grazoprevir (7%), glecaprevir/pibrentasvir (4%), sofosbuvir/velpatasvir/voxilaprevir (1.5%), and other therapies including ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir (0.4%). These therapies were either given alone or in combination with ribavirin (RBV).
- || sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. (Pubmed Central) - Sep 12, 2020
These therapies were either given alone or in combination with ribavirin (RBV). The effect of SOF/VEL therapy is lower for patients with Child C. Improvement of hepatic function is expected after viral eradication with SOF/VEL therapy in patients with decompensated cirrhosis.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-World Evidence: Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. (Pubmed Central) - Sep 9, 2020
Twelve weeks of sofosbuvir/velpatasvir in real-world clinical practice yielded high SVR rates and acceptable safety profiles in decompensated cirrhotic patients with genotypes 1 and 2. Achievement of SVR not only restored the liver functional reserve but also reduced or spared the administration of drugs for related complications.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
PK/PD data, Review, Journal: Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. (Pubmed Central) - Sep 5, 2020
We briefly discuss the relationship between the pharmacokinetics of the DAAs and efficacy or toxicity in special populations, such as hard to cure patients and patients with liver cirrhosis, liver transplantation, renal impairment, hepatitis B virus or HIV co-infection, bleeding disorders, and children. The aim of this overview is to educate/update prescribers and pharmacists so that they are able to safely and effectively treat HCV-infected patients even in the presence of underlying co-infections or co-morbidities.